Member Info for mannnan

delayed buy popped up

Motif Bio believes iclaprim can save hospitals, and patients, money by reducing the amount of after-care required for patients who develop kidney complications as a result of taking vancomycin.

At the moment, just over 9% of hospitalised ABSSSI patients treated with vancomycin suffer from vancomycin-associated acute kidney injury, which extends hospital length-of-stay by five days.

Generally, those patients require a specialist nephrology physician consultation and acute dialysis, which can be costly.

well 1.70 about to hit in 2 minute forget about 30 minute

1.5625 paid

look like 1.70 .............by close let.s see what happen in next 30 minute

In the studies, no deaths were reported among the iclaprim-treated patients compared to three in the vancomycin group.

Motif also repeated that its drug was found not to negatively affect patients’ kidney function, a key issue for some people taking rival treatments.

None of the patients taking iclaprim showed signs of kidney toxicity, whereas seven patients did in the vancomycin arm.

The latest data from two phase III studies looking at the effect of the drug on patients with acute bacterial skin and skin structure infections (ABSSSI) showed that the antibiotic just as good as (the technical term is ‘non-inferior to’) the current gold standard medication, vancomycin.

Importantly though, it looks to be safer, especially in obese patients or those with kidney issues

monday ...over 2p

can,not agree with you .always you are wrong ...like aeg

no.......................no more

;)

on the ask

way over the ask

(POLX.L) is in Phase 3 trials

gone down

1.50 ....or 1.25 ......at the end of the day me think

on the ask ...........nice tick up

.

The firm is proposing to extend the term of the debt to 31 December 2019 following the expiration of the CPN on 31 December 2018. Amphion said that a further announcement will be made in this regard in due course.

WellGen Inc., a nutraceutical company of which Amphion holds a 27% stake, has signed a license agreement with two Missouri-based beverage companies: Sportables LLC and One11 Innovation.
WellGen will receive 11% of the profits derived from the commercial development and sale of Workout Tea™. WorkOut Tea™ a fitness beverage based on a patented and clinically proven anti-inflammatory ingredient derived from a black tea extract. It is sold in the US in a number of flavours.
WellGen is targeting the rapidly growing sports beverage market estimated to reach US$6bn by 2021 (2016 estimate: US$4.6b), according to OrbisResearch.com. Amphion’s other partner companies continue to make progress. Polarean Imaging (POLX.L) is in Phase 3 trials for its novel drug-device platform and Motif Bio (MTFB.L) is awaiting an FDA approval decision for its next generation antibiotic.